Dr Oliver Hanemann

Consultant Neurologist, University Hospitals Plymouth NHS Trust

Director Institute of Translational and Stratified Medicine, PU Peninsula Medical School


I trained at Medical School in Hamburg, Glasgow, Johns Hopkins and Harvard.  After a DFG research fellowship in molecular neurobiology I was neurology registrar at Medical School in Düsseldorf.  From 2000 I was consultant incl. clinical outpatient lead and senior lecturer at the medical school in Ulm continuing my work on brain tumours and motor neuropathies.  During that time, I was also trained as a medical geneticist. In 2005 I became chair of clinical neurobiology at the Peninsula medical school establishing clinical neurobiology research at PU PSMD.  I work as a neurology consultant and my own research at PU PSMD focusses on low grade brain tumours and clinical trials for motor neuron disease.

Since 2014 I have lead the centre of excellence on low grade brain tumours funded by Brain Tumour Research. Our centre has built up a low grade glioma collection and works close to the clinic.

I have and had a number of senior roles within the SW

I have been Associate Medical Director for R&D Plymouth Hospital NHS Trust and Academic lead department of Neurology PHNT.

In my current role as Director of the Institute for Translational and Stratified Medicine at PU Peninsula Schools of Medicine and Dentistry (PU PSMD) my remit is to champion research across traditional boundaries and focus on world-leading research at PU PSMD.

From 2014-2017 I have been Associate Dean of Research for PU PSMD and since 2016 I am member of Plymouth University senate.

Nationally and internationally I am member off

Council of the British Neurooncology Society and have led the research committee for 3 years
The translation and new agents Brain tumour group of the NCRI (now meningioma and metastasis group) and was on the Brain Tumours NCRI CSG.
Member of MND CSG and portfolio management group
The scientific advisory board of a number of charities including the Children’s Tumour Foundation and Brain Research Trust
I am reviewer for more than 20 journal and numerous granting agencies including. DFG, MRC, Cancer Research UK

Invited lectures over 45

Higher degree supervisions 19 primary and 10 secondary

Grant income previously and finished around 2.3 Mill (incl CR UK), currently, Brain Tumour Research, The Brain Tumour Charity, Dr Hadwen Trust and Takeda

Selected publication of over 120, 2016 h-index 34

Hanemann CO, Blakeley JO, et al. (2016) Current status and recommendations for biomarkers in Neurofibromatosis 1, Neurofibromatosis 2 and schwannomatosis, Neurology Aug 16;87(7 Suppl 1):S40-8.
Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder J, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M Hanemann CO (2016) The scaffold protein KSR1, a novel therapeutic target for the treatmentbof merlin defiient tumousr, Oncogene, 35(26):3443-53
McDermott, PJ Shaw, T Stavroulakis, SJ Walters, A Al-Chalabi, S Chandran, F Crawley, D Dick, C Donaghy, P Eames, M Fish, C Gent, G Gorrie, H Hamdalla, CO Hanemann, M Johnson, T Majeed, A Malaspina, K Morrison, R Orrell, A Pinto, A Radunovic, M Roberts, K Talbot, MR Turner, T Williams, C Young (2015) Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study Lancet Neurology 14 (7), 702-709
CJ McDermott,MJ Bradburn, C Maguire, CL Cooper, WO Baird, SK Baxter; SC Bourke; I Imam; A Bentley; J Ealing; M Elliott; CO Hanemann; P Hughes; RW Orrell; PJ Shaw; K Talbot; T Williams;R Ackroyd; R Berrisford; S Galloway; D Karat; N Maynard; A Sarela; C Young; AK Simonds; L Taylor; R Leek; R Darlison (2015) Safety and effi cacy of diaphragm pacing in patients with respiratory insuffi ciency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurology 134(9) 883-892
Wei Li, J Cooper, L Zhou, C Yang, H Erdjument-Bromage, D Zagzag, M Snuderl, M Ladanyi, CO Hanemann, P Zhou, MA. Karajannis and FG Giancotti ( 2014) Merlin/NF2-loss Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Components Lats1 and 2 in the Nucleus, Cancer Cell 14;26(1):48-60
Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, Kelly J, Murphy CL, Al-Chalabi A, Dougherty A, Leigh PN, Wijesekera L, Thornhill M, Ellis CM, O’Hanlon K, Panicker J, Pate L, Ray P, Wyatt L, Young CA, Copeland L, Ealing J, Hamdalla H, Leroi I, Murphy C, O’Keeffe F, Oughton E, Partington L, Paterson P, Rog D, Sathish A, Sexton D, Smith J, Vanek H, Dodds S, Williams TL, Steen IN, Clarke J, Eziefula C, Howard R, Orrell R, Sidle K, Sylvester R, Barrett W, Merritt C, Talbot K, Turner MR, Whatley C, Williams C, Williams J, Cosby C, Hanemann CO, Iman I, Philips C, Timings L, Crawford SE, Hewamadduma C, Hibberd R, Hollinger H, McDermott C, Mils G, Rafiq M, Shaw PJ, Taylor A, Waines E, Walsh T, Addison-Jones R, Birt J, Hare M, Majid T. (2013) Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2013 Apr;12(4):339-45
Hobson EV, McGeachan A, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Ealing J, Ellis CM, Gorrie G, Hanemann CO, Harrower T, Jung A, Majeed T, Malaspina A, Morrison K, Orrell RW, Pall H, Pinto A, Talbot K, Turner MR, Williams TL, Young CA, Shaw PJ, McDermott CJ Management of sialorrhoea in motor neuron disease: A survey of current UK practice Amyotroph Lateral Scler Frontotemporal Degener. 2013 May 7, epub
I Sher, CO Hanemann, PA Karplus, and AP Bretscher (2012). The tumor suppressor merlin controls growth in its open state and is converted to an inactive closed state by phosphorylation, Dev Cell 22(4):703-5.